MA34964B1 - Dérivés de pipéridine pontés - Google Patents

Dérivés de pipéridine pontés

Info

Publication number
MA34964B1
MA34964B1 MA36238A MA36238A MA34964B1 MA 34964 B1 MA34964 B1 MA 34964B1 MA 36238 A MA36238 A MA 36238A MA 36238 A MA36238 A MA 36238A MA 34964 B1 MA34964 B1 MA 34964B1
Authority
MA
Morocco
Prior art keywords
piperidine derivatives
heteroatoms selected
membered
heteroaryl
heteroaryl group
Prior art date
Application number
MA36238A
Other languages
English (en)
Inventor
Karlheinz Baumann
Luke Green
Anja Limberg
Thomas Luebbers
Andrew Thomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34964B1 publication Critical patent/MA34964B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention porte sur des composés de formule (I), dans laquelle hétéroaryle I représente un groupe hétéroaryle à cinq ou six chaînons, contenant 1 à 3 hétéroatomes choisis entre S et N ; hétéroaryle II représente un groupe hétéroaryle à six chaînons, contenant 1 à 3 hétéroatomes choisis entre S et N, ou représente un système cyclique à deux éléments contenant 1 à 4 hétéroatomes choisis entre S et N, au moins un noyau étant aromatique par nature ; R
MA36238A 2011-03-02 2012-02-28 Dérivés de pipéridine pontés MA34964B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11156587 2011-03-02
PCT/EP2012/053301 WO2012116965A1 (fr) 2011-03-02 2012-02-28 Dérivés de pipéridine pontés

Publications (1)

Publication Number Publication Date
MA34964B1 true MA34964B1 (fr) 2014-03-01

Family

ID=45757448

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36238A MA34964B1 (fr) 2011-03-02 2012-02-28 Dérivés de pipéridine pontés

Country Status (22)

Country Link
US (1) US8703763B2 (fr)
EP (1) EP2681214B1 (fr)
JP (1) JP5753591B2 (fr)
KR (1) KR101550122B1 (fr)
CN (1) CN103403003B (fr)
BR (1) BR112013021924A2 (fr)
CA (1) CA2824239A1 (fr)
CL (1) CL2013002474A1 (fr)
CO (1) CO6761320A2 (fr)
CR (1) CR20130358A (fr)
EA (1) EA025035B1 (fr)
EC (1) ECSP13012858A (fr)
IL (1) IL227251A (fr)
MA (1) MA34964B1 (fr)
MX (1) MX2013009031A (fr)
MY (1) MY167264A (fr)
PE (1) PE20140250A1 (fr)
PH (1) PH12013501658A1 (fr)
SG (1) SG193239A1 (fr)
UA (1) UA110368C2 (fr)
WO (1) WO2012116965A1 (fr)
ZA (1) ZA201305322B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133300A1 (fr) * 2007-04-25 2008-11-06 Nissan Chemical Industries, Ltd. Précurseur de polyimide, polyimide et solution de revêtement pour un film de sous-couche pour une formation d'image
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
WO2017042114A1 (fr) 2015-09-09 2017-03-16 F. Hoffmann-La Roche Ag Dérivés de pipéridine pontés
AU2016353961B2 (en) 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
EP3386978B1 (fr) * 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Dérivés de pipéridine pontés
CA3119019C (fr) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Composes et methodes pour traiter la maladie de huntington
CN109311878B (zh) * 2016-06-27 2022-05-24 豪夫迈·罗氏有限公司 作为γ-分泌酶调节剂的三唑并吡啶类化合物
JP6980751B2 (ja) 2016-07-14 2021-12-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 縮合ピリミジン誘導体
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
AR109829A1 (es) * 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
EP3523304B1 (fr) * 2016-10-04 2021-01-27 H. Hoffnabb-La Roche Ag Dérivés hétéroaryles bicycliques
EP3535266B1 (fr) * 2016-11-01 2021-12-29 F. Hoffmann-La Roche AG Dérivés hétéroaryle bicycliques
US11319314B2 (en) 2016-11-08 2022-05-03 Hoffmann-La Roche Inc. Phenoxytriazoles
EP3554502A4 (fr) 2016-12-16 2021-01-06 Pipeline Therapeutics, Inc. Méthodes de traitement de la synaptopathie cochléaire
EP4151627A1 (fr) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Composés permettant de traiter la maladie de huntington
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
EP3672971B1 (fr) * 2017-12-19 2021-07-14 Boehringer Ingelheim International GmbH Triazolopyridines en tant que modulateurs de gamma-sécrétase
US11370802B2 (en) 2018-01-22 2022-06-28 Hoffmann-La Roche, Inc. Triazolo-azepine derivatives
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (fr) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Composés hétéroaryles pour le traitement de la maladie de huntington
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
MX2021002087A (es) * 2018-09-03 2021-04-28 Hoffmann La Roche Derivados de heteroarilo biciclicos.
AU2019395774B2 (en) * 2018-12-13 2024-12-12 F. Hoffmann-La Roche Ag 7-phenoxy-N-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of Alzheimer's disease
AU2019412747B8 (en) * 2018-12-27 2025-04-24 F. Hoffmann-La Roche Ag Process for the preparation exo-tert-butyl N-(3-azabicyclo[3.2.1]octan-8-yl)carbamate
CA3139821A1 (fr) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Composes pour le traitement de la maladie de huntington
CN113372364B (zh) * 2020-03-10 2024-05-31 明慧医药（上海）有限公司 一类jak激酶抑制剂及其制备和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432985B2 (en) 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
EP1932844B1 (fr) * 2005-10-06 2015-09-02 Nippon Soda Co., Ltd. Composés amines cycliques réticulés et agents pesticides
KR101247840B1 (ko) 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines

Also Published As

Publication number Publication date
IL227251A (en) 2016-09-29
SG193239A1 (en) 2013-10-30
ZA201305322B (en) 2014-04-30
EA201391209A1 (ru) 2013-12-30
CN103403003B (zh) 2016-09-14
MY167264A (en) 2018-08-14
JP2014506903A (ja) 2014-03-20
KR101550122B1 (ko) 2015-09-03
PE20140250A1 (es) 2014-03-12
IL227251A0 (en) 2013-09-30
US8703763B2 (en) 2014-04-22
CN103403003A (zh) 2013-11-20
NZ612525A (en) 2015-08-28
EA025035B1 (ru) 2016-11-30
JP5753591B2 (ja) 2015-07-22
CO6761320A2 (es) 2013-09-30
PH12013501658A1 (en) 2013-10-07
EP2681214A1 (fr) 2014-01-08
CL2013002474A1 (es) 2014-05-30
BR112013021924A2 (pt) 2020-10-20
MX2013009031A (es) 2013-09-02
AU2012222426A1 (en) 2013-07-11
WO2012116965A1 (fr) 2012-09-07
UA110368C2 (xx) 2015-12-25
EP2681214B1 (fr) 2017-03-22
KR20130140142A (ko) 2013-12-23
CR20130358A (es) 2013-10-03
CA2824239A1 (fr) 2012-09-07
ECSP13012858A (es) 2013-10-31
US20120225884A1 (en) 2012-09-06

Similar Documents

Publication Publication Date Title
MA35172B1 (fr) Melanges pestticides contenant des derives d&#39;isoxazoline
MA38540B1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l&#39;intégrine alpha-v-bêta-6
MA37519A1 (fr) Composés et compositions pour inhiber l&#39;activité d&#39;abl1, abl2 et bcr-abl1
MA34006B1 (fr) Derives de dihydrofurane utilises comme composes insecticides
MA32171B1 (fr) Compose heterocyclique
EA201290401A1 (ru) Азотсодержащее гетероциклическое соединение и сельскохозяйственный фунгицид
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA33275B1 (fr) Inhibiteurs de la replication du virus de l&#39;immunodeficience humaine
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA31759B1 (fr) Compose amide
MA31118B1 (fr) Procede de preparation d&#39;un derive de benzimidazole
EA201491936A1 (ru) Азотсодержащее гетероциклическое соединение
UA110647C2 (uk) Похідне азолу, спосіб його одержання, проміжна сполука і хімічний агент, призначений для застосування в сільському господарстві і садівництві, і агент для захисту промислових матеріалів
MY169179A (en) Novel piperidine compound or salt thereof
MA35893B1 (fr) Dérivés d&#39;amide hétérocyclique comme antagonistes du récepteur p2x7
MA32173B1 (fr) Derives de pyridin-2-yle utilises comme agents immunomodulateurs
MA38112A1 (fr) Dérivés d&#39;imidazopyridazine en tant que modulateurs d&#39;un récepteur gabaa
MA38948A1 (fr) Dérivés de 2h-indazole antibactériens
MA33618B1 (fr) Agent thérapeutique destiné aux troubles de l&#39;humeur
MA38275A1 (fr) Hétérocycles azotés saturés et n-acylés potentialisant l&#39;activité d&#39;un antibiotique actif contre les mycobactéries
TN2015000490A1 (fr) Dérivés d&#39;imidazo-triazine servant d&#39; inhibiteurs de pde10
AR088564A1 (es) PROCESO PARA LA PREPARACION DE AGONISTAS Y COMPUESTOS INTERMEDIOS DE b3
MA37719A1 (fr) Dérivés de pyrimidinone en tant qu&#39;agents anti-malaria
MA38410B1 (fr) Composés d&#39;azétidinyloxyphénylpyrrolidine
AR081034A1 (es) Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central